30 C
Delhi
Saturday, August 30, 2025

Alembic Pharma receives USFDA final approval for Prazosin Hydrochloride Capsules

Date:

Share post:

Donate-GC-Razorpay

Mumbai: Pharma major, Alembic Pharma on Wednesday said it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg, and 5 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Minipress Capsules, 1 mg, 2 mg, and 5 mg, of Pfizer Inc. Prazosin Hydrochloride Capsule is indicated for the treatment of hypertension, to lower blood pressure. Refer to our label for full indication.

Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg, and 5 mg have an estimated market size of US$ 50 million for twelve months ending Dec 2022, according to IQVIA.

Related articles

Self-reliance in Defence is not merely an option, but a condition for survival & progress: Rajnath Singh

New Delhi: Defence Minister Rajnath Singh said that in today’s era of terrorism, pandemics and regional conflicts, self-reliance...

Putin advocates reforms in UN, IMF to reflect modern realities

Moscow/Beijing: Russian President Vladmir Putin, ahead of the upcoming SCO summit in the Chinese city of Tianjin, lauded...

India’s GDP surges 7.8 pc in Q1 FY 26, led by services and manufacturing

New Delhi: India’s economy sprinted ahead in the first quarter of FY 2025-26, with real Gross Domestic Product...

India crush Nepal 5-0 to clinch SAFF U17 Women’s Championship 2025 title

New Delhi/Thimphu: India’s dominance in South Asian football continued as the U 17 women’s team thrashed Nepal 5-0...